+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Screening for celiac disease in Down's syndrome patients revealed cases of subtotal villous atrophy without typical for celiac disease HLA-DQ and tissue transglutaminase antibodies



Screening for celiac disease in Down's syndrome patients revealed cases of subtotal villous atrophy without typical for celiac disease HLA-DQ and tissue transglutaminase antibodies



World Journal of Gastroenterology 12(9): 1430-1434



To investigate the prevalence of celiac disease (CD) as well as CD marker antibodies and susceptibility HLA-DQ haplotypes in 134 karyotyped Down's syndrome (DS) patients. Immunoglobulin A (IgA) and G (IgG) type anti-gliadin antibodies (AGA), IgA type anti-tissue transglutaminase (tTG) antibodies (anti-tTG) with antigen of guinea pig and human source were determined by enzyme-linked immunosorbent assay and endomysium antibodies (EMA) by indirect immunofluorescence test. HLA-DQA1*0501/DQB1*0201 (DQ2) was revealed by polymerase chain reaction. Celiac disease was diagnosed by revised ESPGHAN criteria. 41% of DS patients had AGA, 6.0% IgA anti-tTG with guinea pig antigen, and 3.0% IgA EMA (all positive for anti-tTG with human tTG). Subtotal villous atrophy was found in 5 out of 9 DS patients who had agreed to small bowel biopsy. One of them had DQA1*0501/DQB1*0201 and anti-tTG and EMA i.e. typical for CD markers (this case also fulfilled the ESPGHAN diagnostic criteria),but other four lacked these markers. Three non-biopsied DS patients had also most probably CD because DQA1*0501/DQB1*0201 and IgA anti-tTG (EMA) were detected. Thus, the prevalence of CD among our DS patients population is 3.0% (95 % of confidence interval [CI]: 0.1-5.9%). We confirm the increased frequency of CD among DS patients. In addition, we have revealed a subgroup of patients with subtotal villous atrophy but without characteristic for CD immunological and genetic markers. Whether these cases represent CD (with atypical immunopathogenesis) or some other immune enteropathy, requires further investigations.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 050263025

Download citation: RISBibTeXText

PMID: 16552815


Related references

M2054 Correlation of Histological Villous Atrophy with Tissue Transglutaminase Antibody Level in Patients with Diagnosis of Celiac Disease: Retrospective Analysis of a Cohort of 187 Celiac Patients. Gastroenterology 136(5): A-475-A-476, 2009

Tests for Serum Transglutaminase and Endomysial Antibodies Do Not Detect Most Patients With Celiac Disease and Persistent Villous Atrophy on Gluten-free Diets: a Meta-analysis. Gastroenterology 153(3): 689-701.E1, 2017

Nutritional status of newly diagnosed celiac disease patients before and after the institution of a celiac disease diet--association with the grade of mucosal villous atrophy. American Journal of Clinical Nutrition 67(3): 482-487, 1998

High tissue-transglutaminase antibody level predicts small intestinal villous atrophy in adult patients at high risk of celiac disease. Digestive and Liver Disease 44(4): 280-285, 2012

S2027 Is Villous Atrophy Predictable by High Tissue-Transglutaminases Antibodies (T-Tga) Level in Unselected Adult Patients Evaluated for Celiac Disease (Cd)?. Gastroenterology 138(5): S-304, 2010

Tissue transglutaminase antibodies are a useful serological marker for the diagnosis of celiac disease in patients with Down syndrome. Journal of Pediatric Gastroenterology and Nutrition 44(5): 583-586, 2007

Screening for celiac disease in Tunisian patients with Graves' disease using anti-endomysium and anti-tissue transglutaminase antibodies. Gastroenterologie Clinique et Biologique 30(8-9): 961-964, 2006

Mo1859 Eosinophilic Esophagitis and Elevated Tissue Transglutaminase (TTG) Antibodies in the Absence of Celiac Disease Non-Celiac Gluten Sensitivity in the Esophagus?. Gastroenterology 146(5): S-674-S-675, 2014

Value of IgA antibodies to human recombinant tissue transglutaminase in the serological screening for celiac disease. Gastroenterology. 122(4 Suppl. 1): A-182, Il, 2002

Celiac anti-type 2 transglutaminase antibodies induce differential effects in fibroblasts from celiac disease patients and from healthy subjects. Amino Acids 49(3): 541-550, 2017

Value of a screening algorithm for celiac disease using tissue transglutaminase antibodies as first level in a population-based study. American Journal of Gastroenterology 97(11): 2785-2790, 2002

Celiac disease can be predicted by high levels of anti-tissue transglutaminase antibodies in population-based screening. Journal of Pediatric Gastroenterology and Nutrition 60(6): 787-791, 2015

Fully-automated, chemiluminescence IgA and IgG anti-tissue transglutaminase (tTG) antibodies serum assays for the screening of celiac disease. Journal of Immunological Methods 429: 57-59, 2016

Evaluating diagnostic accuracy of anti-tissue Transglutaminase IgA antibodies as first screening for Celiac Disease in very young children. Clinica Chimica Acta; International Journal of Clinical Chemistry 446: 237-240, 2015

Prevalence of celiac disease in children with Down syndrome screened by anti-tissue transglutaminase antibodies. Saudi Medical Journal 33(2): 208-210, 2012